Compare STMicroelectronics NV (STM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs Tango Therapeutics Inc. — how do they compare? STMicroelectronics NV trades at $44.87 (market cap $43.15B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: STMicroelectronics NV is far larger — about 11.5× Tango Therapeutics Inc.'s market cap, and STMicroelectronics NV pays a 0.77% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold STMicroelectronics NV for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| STM | TNGX | |
|---|---|---|
Market Cap | $43.15B | $3.74B |
Volume | 14,115,128 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $79.91 | $32.90 |
52-Week Low | $21.20 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $40.67B | $2.76B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM trades at $49.57, down 1.8% on the day, with a bearish technical signal but strong analyst support. The company reported mixed Q2 2026 earnings, beating expectations with $0.31 EPS versus $0.26 expected, while revenue trends show recovery with 26% year-on-year growth in Q2. Valuation metrics appear elevated with a P/E of 94.59, but the company maintains solid cash flow and a strong balance sheet with $6.18 billion in cash.
STM faces near-term profitability challenges with negative net income margins, but strong AI data-center revenue growth projections to exceed $2 billion by 2027 provide upside potential. Key risks include execution on margin improvement and competitive pressures in semiconductor markets. Analyst consensus remains bullish with a $77.31 price target representing 56% upside from current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
